DNTH (Dianthus Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by DNTH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Simon Read | Director | MIXED | — | — |
| 2026-08-14 | Adam M Veness | SVP, General Counsel and Sec. | M | — | — |
| 2026-08-11 | Simon Read | Director | MIXED | — | — |
| 2026-08-11 | Anne McGeorge | Director | MIXED | — | — |
| 2026-08-11 | Adam M Veness | SVP, General Counsel and Sec. | MIXED | — | — |
| 2026-08-07 | Marino Garcia | CEO AND PRESIDENT | MIXED | — | — |
| 2026-08-07 | Marino Garcia | CEO AND PRESIDENT | MIXED | — | — |
| 2026-07-13 | Ryan Savitz | EVP, CFO & CBO | MIXED | — | — |
| 2026-06-18 | Adam M Veness | SVP, General Counsel and Sec. | MIXED | — | — |
| 2026-06-02 | Simrat Randhawa | EVP, Head of R&D | MIXED | — | — |
| 2026-05-22 | SUJAY KANGO | Director | A | — | — |
| 2026-05-22 | Alison Frances Lawton | Director | A | — | — |
| 2026-05-22 | Paula Soteropoulos | Director | A | — | — |
| 2026-05-22 | Anne McGeorge | Director | A | — | — |
| 2026-05-22 | Steven J. Romano | Director | A | — | — |
| 2026-05-22 | Simon Read | Director | A | — | — |
| 2026-05-22 | Jonathan Violin | Director | A | — | — |
| 2026-05-11 | Paula Soteropoulos | Director | MIXED | — | — |
| 2026-04-10 | Ryan Savitz | EVP, CFO & CBO | MIXED | — | — |
| 2026-04-01 | Paula Soteropoulos | Director | MIXED | — | — |
| 2026-04-01 | Ryan Savitz | EVP, CFO & CBO | MIXED | — | — |
| 2026-03-26 | Paula Soteropoulos | Director | MIXED | — | — |
| 2026-03-17 | Marino Garcia | CEO AND PRESIDENT | M | — | — |
| 2026-03-13 | Simrat Randhawa | EVP, Head of R&D | MIXED | — | — |
| 2026-03-13 | Marino Garcia | CEO AND PRESIDENT | MIXED | — | — |
| 2026-03-13 | EDWARD CARR | CHIEF ACCOUNTING OFFICER | MIXED | — | — |
| 2026-02-04 | Simrat Randhawa | EVP, Head of R&D | A | — | — |
| 2026-02-04 | Marino Garcia | CEO AND PRESIDENT | A | — | — |
| 2026-02-04 | Adam M Veness | SVP, General Counsel and Sec. | A | — | — |
| 2026-02-04 | Ryan Savitz | EVP, CFO & CBO | A | — | — |
| 2026-02-04 | EDWARD CARR | CHIEF ACCOUNTING OFFICER | A | — | — |
| 2025-12-05 | Ryan Savitz | CFO & CBO | MIXED | — | — |
| 2025-11-14 | Simrat Randhawa | EVP, Head of R&D | MIXED | — | — |
| 2025-10-03 | Marino Garcia | CEO AND PRESIDENT | A | — | — |
| 2025-09-25 | Ryan Savitz | CFO & CBO | A | — | — |
| 2025-09-25 | Simrat Randhawa | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-09-11 | Ryan Savitz | CFO & CBO | MIXED | — | — |
| 2025-05-22 | Jonathan Violin | Director | A | — | — |
| 2025-05-22 | Paula Soteropoulos | Director | A | — | — |
| 2025-05-22 | Anne McGeorge | Director | A | — | — |
| 2025-05-22 | Alison Frances Lawton | Director | A | — | — |
| 2025-05-22 | Steven J. Romano | Director | A | — | — |
| 2025-05-22 | Simon Read | Director | A | — | — |
| 2025-03-05 | SUJAY KANGO | Director | A | — | — |
| 2025-02-04 | Simrat Randhawa | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-02-04 | Ryan Savitz | CFO & CBO | A | — | — |
| 2025-02-04 | Adam M Veness | SVP, General Counsel and Sec. | A | — | — |
| 2025-02-04 | Marino Garcia | CEO AND PRESIDENT | A | — | — |
| 2025-02-04 | EDWARD CARR | CHIEF ACCOUNTING OFFICER | A | — | — |
| 2024-10-01 | Tomas Kiselak | Director | J | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,717,554 | — |
| — | Director | 1,928,503 | — |
| — | Director | 1,436,745 | — |
| — | CEO AND PRESIDENT | 197,001 | — |
| — | Director | 62,146 | — |
| — | SVP, General Counsel and Sec. | 15,000 | — |
| — | EVP, Head of R&D | 7,998 | — |
| — | Director | 7,750 | — |
| — | CHIEF ACCOUNTING OFFICER | 300 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DNTH quote page; the site-wide leaderboard is on the insider transactions hub.